J
John G.F. Cleland
Researcher at National Institutes of Health
Publications - 1276
Citations - 125527
John G.F. Cleland is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Heart failure & Ejection fraction. The author has an hindex of 137, co-authored 1172 publications receiving 110227 citations. Previous affiliations of John G.F. Cleland include Northwestern University & Imperial College London.
Papers
More filters
Journal ArticleDOI
Comparison of selective ETA and ETB receptor antagonists in patients with chronic heart failure
Peter J. Cowburn,John G.F. Cleland,Theresa McDonagh,John D. McArthur,Henry J. Dargie,James J. Morton +5 more
TL;DR: The vasoconstrictor action of endothelin‐1 (ET‐1) is mediated through ETA and ETB receptor subtypes on vascular smooth muscle as well as on the vascular endothelium where they mediate vasodilation.
Journal ArticleDOI
Predicting peak oxygen uptake from 6-min walk test performance in male patients with left ventricular systolic dysfunction.
TL;DR: In patients with left ventricular systolic dysfunction (LVSD), peak oxygen uptake (pV̇O2) has strong predictive power for mortality, and can be used to guide management, and if closely related could allow substitution of an expensive and cumbersome test for a cheaper and more familiar one.
Journal ArticleDOI
The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy: who benefits the most?
Claire E. Raphael,Judith A. Finegold,Anthony J. Barron,Zachary I. Whinnett,Jamil Mayet,Cecilia Linde,John G.F. Cleland,Wayne C. Levy,Darrel P. Francis +8 more
TL;DR: While high-risk patients may show the greatest short-term gain, the dramatic growth of lifespan-gain over time means that it is the lower risk patients, e.g. primary prevention ICD implantation, who gain the most life-years over their lifetime.
Journal ArticleDOI
Clinical trials update from the Heart Failure Society of America and the American Heart Association meetings in 2008: SADHART-CHF, COMPARE, MOMENTUM, thyroid hormone analogue study, HF-ACTION, I-PRESERVE, β-interferon study, BACH, and ATHENA
TL;DR: This article provides information and a commentary on trials relevant to the pathophysiology, prevention, and treatment of heart failure presented at the Heart Failure Society of America and the American Heart Association meetings in 2008.
Journal ArticleDOI
Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study.
Gad Cotter,Marco Metra,Beth A. Davison,Stefanie Senger,Robert C. Bourge,John G.F. Cleland,John G.F. Cleland,Guillaume Jondeau,Henry Krum,Christopher M. O'Connor,John D. Parker,Guillermo Torre-Amione,Dirk J. van Veldhuisen,Olga Milo,Isaac Kobrin,Maurizio Rainisio,John J.V. McMurray,John R. Teerlink +17 more
TL;DR: Worsening heart failure in the first 7 days after an admission for acute HF (AHF) has been proposed as a therapeutic target in several recent AHF studies and was a co‐primary endpoint of the VERITAS studies.